ATRC
AtriCure, Inc.
$34.28
-0.28 (-0.81%)
At close · Jul 10
Market Cap
$1.74B
Shares
50,640,970
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$34.28
Open$34.81
Day$33.43–34.81
52W$25.36–43.18
Avg vol 30d942K
Short int4.4M · 8.8% float · 3.6d
Short vol75%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
+20%
above
RSI (14)
71
overbought
MACD trend
Positive
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+25%
trailing
6-month return
−17%
trailing
YTD return
−13%
this year
Relative strength
−26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $33 — 200d above 50d
Institutional flow
Accumulating
6 of 222 funds reported for Jun 30 · net +76.7K sh shares · +3 new
Insider flow
Distributing
Net -$226.6K over 90 days · 100% sells
Short interest
Rising
8.79% of float · ▲ +29.2% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
222 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+304%
Y/Y
Gross margin
199%
contracting
EPS growth
+75%
Y/Y
Free cash flow
$48.3M
Balance sheet
$106.4M
net cash
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 5, 2026
Worldwide revenue
· full year 2026
Initiated
$600M – $610M
prior FY $534.53M
midpoint +13.2% Y/Y
Adjusted EBITDA
· full year 2026
Non-GAAP
Initiated
$80M – $82M
Adjusted earnings per share
· full year 2026
Non-GAAP
Initiated
$0.00 – $0.04
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
71
Bearish
MACD trend
Positive
Bullish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $29 › 200d $33 — 200d above 50d
Institutional flow
Accumulating
6 of 222 funds reported for Jun 30 · net +76.7K sh shares · +3 new
Insider flow
Distributing
Net -$226.6K over 90 days · 100% sells
Short interest
Rising
8.79% of float · ▲ +29.2% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
222 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $25
Now $34 · 50%
52-wk high $43
vs 200-day avg +4%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $17.1M | first quarter 2026 | — |
|
|
|||
| appendage management franchise growth | 16% | Q1 2026 call | — |
| AtriClip FLEX-Mini share of open appendage management revenue | 40% | Q1 2026 call | — |
| BoxX-NoAF clinical trial patients enrolled | 300 | since initiation through Q1 2026 call | — |
| open ablation revenue growth | 15% | Q1 2026 call | — |
| pain management sales growth | 28% | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATRC
this stock
AtriCure, Inc.
|
$1.74B | -13.3% | +19.5% | — | 8.8% |
|
ISRG
Intuitive Surgical Inc
|
$144.07B | -28.2% | +20.5% | 49.4 | 2.1% |
|
MDLN
Medline Inc.
|
$53.91B | -2.3% | +11.5% | — | 2.8% |
|
BDX
Becton Dickinson & Co
|
$41.87B | +0.9% | +8.2% | 57.7 | 4.1% |
|
ALC
Alcon Inc
|
$33.07B | -14.0% | +10.5% | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATRC | +7.8% | +24.6% | -17.3% | +22.5% | -13.4% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +6.5% | +20.5% | -26.4% | +21.4% | -24.1% |